Profile data is unavailable for this security.
About the company
Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.
- Revenue in USD (TTM)9.66bn
- Net income in USD1.17bn
- Incorporated1997
- Employees7.57k
- LocationBiogen Inc225 Binney StreetCAMBRIDGE 02142United StatesUSA
- Phone+1 (781) 464-2000
- Fax+1 (302) 636-5454
- Websitehttps://www.biogen.com/
Mergers & acquisitions
Acquired company | BIIB:NSQ since announced | Transaction value |
---|---|---|
Reata Pharmaceuticals Inc | -11.83% | 7.53bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alnylam Pharmaceuticals, Inc. | 2.00bn | -332.08m | 20.29bn | 2.10k | -- | -- | -- | 10.13 | -2.71 | -2.71 | 15.78 | -1.73 | 0.5552 | 2.85 | 11.67 | 953,969.10 | -9.20 | -26.56 | -11.86 | -32.77 | 83.95 | 83.66 | -16.58 | -94.26 | 3.07 | -1.37 | 1.27 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
ICON PLC | 8.23bn | 683.12m | 25.91bn | 41.10k | 38.02 | 2.75 | 20.35 | 3.15 | 8.24 | 8.24 | 99.33 | 114.08 | 0.4795 | -- | 2.92 | 200,291.60 | 3.98 | 3.93 | 4.80 | 4.80 | 29.67 | 28.91 | 8.30 | 7.37 | -- | 3.48 | 0.2706 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
DuPont de Nemours Inc | 11.98bn | 404.00m | 33.31bn | 24.00k | 91.18 | 1.41 | 20.76 | 2.78 | 0.8736 | 0.8126 | 27.12 | 56.41 | 0.3036 | 3.37 | 4.99 | 499,208.30 | 1.12 | 0.3709 | 1.24 | 0.468 | 35.15 | 35.69 | 3.70 | 1.97 | 1.61 | 6.24 | 0.2446 | 414.03 | -7.29 | -11.79 | -51.19 | 11.24 | -30.66 | -20.59 |
Gartner Inc | 5.97bn | 797.23m | 33.55bn | 20.29k | 43.02 | 47.07 | 33.86 | 5.62 | 10.05 | 10.05 | 75.24 | 9.18 | 0.7915 | -- | 3.80 | 295,054.30 | 10.57 | 8.24 | 19.95 | 14.76 | 67.72 | 67.55 | 13.35 | 12.20 | -- | 13.10 | 0.7738 | -- | 7.87 | 8.24 | 9.24 | 49.78 | -4.06 | -- |
Biogen Inc | 9.66bn | 1.17bn | 33.73bn | 7.57k | 28.95 | 2.22 | 19.87 | 3.49 | 8.00 | 8.00 | 66.40 | 104.48 | 0.3777 | 1.27 | 4.80 | 1,276,499.00 | 4.56 | 12.53 | 5.20 | 14.83 | 75.03 | 81.84 | 12.08 | 26.93 | 1.32 | 3.78 | 0.3007 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
Iqvia Holdings Inc | 15.07bn | 1.36bn | 38.76bn | 87.00k | 29.03 | 6.11 | 15.54 | 2.57 | 7.33 | 7.33 | 81.34 | 34.82 | 0.5761 | -- | 4.64 | 173,206.90 | 5.19 | 3.24 | 6.93 | 4.07 | 35.03 | 34.32 | 9.01 | 6.03 | -- | 3.19 | 0.6809 | 0.00 | 3.98 | 7.55 | 24.47 | 43.39 | 7.17 | -- |
Holder | Shares | % Held |
---|---|---|
PRIMECAP Management Co.as of 31 Mar 2024 | 16.22m | 11.16% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 15.95m | 10.97% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 8.20m | 5.64% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 6.75m | 4.64% |
T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 5.17m | 3.56% |
Wellington Management Co. LLPas of 31 Mar 2024 | 5.12m | 3.52% |
Geode Capital Management LLCas of 31 Mar 2024 | 3.41m | 2.35% |
JPMorgan Investment Management, Inc.as of 31 Mar 2024 | 2.81m | 1.94% |
BlackRock Investment Management (UK) Ltd.as of 31 Mar 2024 | 2.13m | 1.47% |
Van Eck Associates Corp.as of 31 Mar 2024 | 1.74m | 1.20% |